Jessica S Merlin1, Jeffrey H Samet2,3,4, Debbie M Cheng5, Marlene C Lira2, Judith I Tsui6, Leah S Forman7, Jonathan Colasanti8,9, Alexander Y Walley2,3, Carlos Del Rio8,9, Jane M Liebschutz1. 1. Division of General Internal Medicine, Department of Medicine, University of Pittsburgh School of Medicine, Pittsburgh, PA. 2. Clinical Addiction Research and Education Unit, Section of General Internal Medicine, Department of Medicine, Boston Medical Center, Boston, MA. 3. Department of Medicine, Boston University School of Medicine, Boston, MA. 4. Department of Community Health Sciences, Boston University School of Public Health, Boston, MA. 5. Department of Biostatistics, Boston University School of Public Health, Boston, MA. 6. Section of General Internal Medicine, Department of Medicine, University of Washington and Harborview Medical Center, Seattle, WA. 7. Biostatistics and Epidemiology Data Analytics Center (BEDAC), Boston University School of Public Health, Boston, MA. 8. Division of Infectious Diseases, Department of Medicine, Emory University School of Medicine, Atlanta, GA. 9. Hubert Department of Global Health, Rollins School of Public Health, Emory University, Atlanta, GA.
Abstract
BACKGROUND: Medical marijuana is legal in 29 US states and the District of Columbia: both HIV and chronic pain are "approved conditions" for receipt. Chronic pain is common among people living with HIV (PLWH). We anticipate PLWH will question their providers about medical marijuana for chronic pain. We examined marijuana use and its associations with pain, opioid dose, and HIV viral suppression among PLWH receiving chronic opioid therapy. METHODS: PLWH prescribed chronic opioid therapy were recruited into the Targeting Effective Analgesia in Clinics for HIV cohort. The main exposure variable was any past 12-month marijuana use. The primary outcomes were (1) opioid misuse (≥9 on the Current Opioid Misuse Measure) and (2) opioid dose (morphine equivalent daily dose). HIV viral load (VL) suppression (<200 copies/μL) and pain severity and interference using the Brief Pain Inventory were exploratory outcomes. RESULTS: Participants (n = 166) were men (65%), Black (72%), and had an undetectable VL (89%). We found no significant association between current marijuana use and opioid misuse, opioid dose, or pain. Current marijuana use was associated with 3.03 times the odds of having a detectable VL (95% odds ratio: 1.11-8.31, P = 0.03) while controlling for depressive symptoms and other substance use. DISCUSSION: We did not detect an association between marijuana use and opioid misuse behaviors, opioid dose, or pain. In an exploratory analysis, current marijuana use was associated with 3× greater odds of having a detectable VL. This study provides insights into potential consequences of marijuana use among PLWH with chronic pain.
BACKGROUND: Medical marijuana is legal in 29 US states and the District of Columbia: both HIV and chronic pain are "approved conditions" for receipt. Chronic pain is common among people living with HIV (PLWH). We anticipate PLWH will question their providers about medical marijuana for chronic pain. We examined marijuana use and its associations with pain, opioid dose, and HIV viral suppression among PLWH receiving chronic opioid therapy. METHODS: PLWH prescribed chronic opioid therapy were recruited into the Targeting Effective Analgesia in Clinics for HIV cohort. The main exposure variable was any past 12-month marijuana use. The primary outcomes were (1) opioid misuse (≥9 on the Current Opioid Misuse Measure) and (2) opioid dose (morphine equivalent daily dose). HIV viral load (VL) suppression (<200 copies/μL) and pain severity and interference using the Brief Pain Inventory were exploratory outcomes. RESULTS: Participants (n = 166) were men (65%), Black (72%), and had an undetectable VL (89%). We found no significant association between current marijuana use and opioid misuse, opioid dose, or pain. Current marijuana use was associated with 3.03 times the odds of having a detectable VL (95% odds ratio: 1.11-8.31, P = 0.03) while controlling for depressive symptoms and other substance use. DISCUSSION: We did not detect an association between marijuana use and opioid misuse behaviors, opioid dose, or pain. In an exploratory analysis, current marijuana use was associated with 3× greater odds of having a detectable VL. This study provides insights into potential consequences of marijuana use among PLWH with chronic pain.
Authors: Christine Miaskowski; Joanne M Penko; David Guzman; Jennifer E Mattson; David R Bangsberg; Margot B Kushel Journal: J Pain Date: 2011-09 Impact factor: 5.820
Authors: E Jennifer Edelman; Kirsha Gordon; William C Becker; Joseph L Goulet; Melissa Skanderson; Julie R Gaither; Jennifer Brennan Braden; Adam J Gordon; Robert D Kerns; Amy C Justice; David A Fiellin Journal: J Gen Intern Med Date: 2012-08-16 Impact factor: 5.128
Authors: Jocelyn M Jiao; Eric So; Jebakaran Jebakumar; Mary Catherine George; David M Simpson; Jessica Robinson-Papp Journal: Pain Date: 2016-04 Impact factor: 6.961
Authors: Louisa Degenhardt; Nicholas Lintzeris; Gabrielle Campbell; Raimondo Bruno; Milton Cohen; Michael Farrell; Wayne D Hall Journal: Drug Alcohol Depend Date: 2014-12-10 Impact factor: 4.492
Authors: D I Abrams; C A Jay; S B Shade; H Vizoso; H Reda; S Press; M E Kelly; M C Rowbotham; K L Petersen Journal: Neurology Date: 2007-02-13 Impact factor: 9.910
Authors: San Keller; Carla M Bann; Sheri L Dodd; Jeff Schein; Tito R Mendoza; Charles S Cleeland Journal: Clin J Pain Date: 2004 Sep-Oct Impact factor: 3.442
Authors: Stephen F Butler; Simon H Budman; Kathrine C Fernandez; Brian Houle; Christine Benoit; Nathaniel Katz; Robert N Jamison Journal: Pain Date: 2007-05-09 Impact factor: 6.961
Authors: Brian A Perry; Andrew O Westfall; Elizabeth Molony; Rodney Tucker; Christine Ritchie; Michael S Saag; Michael J Mugavero; Jessica S Merlin Journal: J Palliat Med Date: 2013-03-11 Impact factor: 2.947
Authors: Ronald J Ellis; Will Toperoff; Florin Vaida; Geoffrey van den Brande; James Gonzales; Ben Gouaux; Heather Bentley; J Hampton Atkinson Journal: Neuropsychopharmacology Date: 2008-08-06 Impact factor: 7.853
Authors: Leslie W Suen; Vanessa M McMahan; Christopher Rowe; Sumeet Bhardwaj; Kelly Knight; Margot B Kushel; Glenn-Milo Santos; Phillip Coffin Journal: J Am Board Fam Med Date: 2021 Nov-Dec Impact factor: 2.395